Provided by Tiger Trade Technology Pte. Ltd.

ProShares Pet Care ETF

48.31
+0.29790.62%
Post-market: 48.22-0.0881-0.18%19:30 EDT
Volume:735
Turnover:35.43K
Market Cap:31.40M
PE:- -
High:48.31
Open:48.29
Low:48.22
Close:48.01
52wk High:57.44
52wk Low:45.96
Shares:650.00K
Float Shares:650.00K
Volume Ratio:0.63
T/O Rate:0.11%
Dividend:0.36
Dividend Rate:0.75%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Merck & Co - Patient Enrollment Continues in Ideate-Lung02 Phase 3 Trial for Ifinatamab Deruxtecan

THOMSON REUTERS
·
Sep 26

Merck & Co - Two Additional Phase 3 Trials Underway for Ifinatamab Deruxtecan in Crpc and Escc

THOMSON REUTERS
·
Sep 26

Innovation is Driving a New Bull Market in Biotech. 16 Ways to Play It, from Our Roundtable Experts.

Dow Jones
·
Sep 25

FDA Approves Merck’s Welireg Plus Eisai’s Lenvima for Previously Treated Advanced Clear Cell Kidney Cancer

Reuters
·
Sep 25

Surrozen price target raised to $54 from $44 at H.C. Wainwright

TIPRANKS
·
Sep 25

Zoetis Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25

Revvity Inc. Stock Climbs 6.0%, Outperforms Peers

Dow Jones
·
Sep 25

FDA approves Welireg and Lenvima combo for ccRCC

TIPRANKS
·
Sep 25

Merck Shares Flat in Volume Spike After FDA Approves Kidney Drug, Last up 0.50% at $148.81

THOMSON REUTERS
·
Sep 25

FDA Approves Belzutifan in Combination with Lenvatinib for Advanced Renal Cell Carcinoma with a Clear Cell Component

THOMSON REUTERS
·
Sep 25

Zoetis put volume heavy and directionally bearish

TIPRANKS
·
Sep 25

Merck Has Two Overlooked Pipeline Catalysts Coming Before Year-End, UBS Says

MT Newswires Live
·
Sep 25

Zoetis Schedules Webcast, Conference Call on Third-Quarter Results

Reuters
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24